Clinical trials: Coronary Stent Occlusion
Cardiovascular Diseases, Coronary Artery Disease
The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions
The registry aims to evaluate the safety, performance and efficacy of the Everolimus-eluting bioresorbable vascular scaffold (BVS) system following rotational atherectomy in patients with complex de novo native coronary artery…
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
- Trial name
- ASSURE ROT (NCT01915420)
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.
Coronary Artery Disease
A Trial of DCB vs DES in the Treatment of de Novo Large Diameter Coronary Atherosclerotic Stenosis(LARGE ONE)
For the treatment of primary large-diameter coronary atherosclerosis through percutaneous coronary intervention (PCI), the use of a drug balloon (DCB) is not inferior to the placement of a drug-eluting stent (Firehawk™ family).
- Trial name
- LARGE-ONE (NCT05961787)
- Testing
- SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
RESOLUTE ONYX Post-Approval Study
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.
- Trial name
- ONYX PAS (NCT03063749)
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Where
- 28 sites in United States, Belgium and 2 more
- Volunteers
- 416 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
IRIS Ultimaster Cohort in the IRIS-DES Registry
The purpose of this study is to evaluate the relative effectiveness and safety of Ultimaster stent compared to other drug eluting stents.
- Trial name
- IRISUltimaster (NCT02719106)
- Testing
- Ultimaster stent
- Where
- 15 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- Duk-Woo Park, MD
Coronary Artery Disease, Coronary Artery Stenosis
ABSORB III Randomized Controlled Trial (RCT)
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB-III (NCT01751906)
- Testing
- Absorb BVS, XIENCE
- Where
- 192 sites in United States, Australia
- Volunteers
- 2,008 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Intravascular Ultrasound Guided Drug Eluting Stents Implantation in "All-comers" Coronary Lesions （ULTIMATE Trial）
A number of 1448 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and IVUS imaging are openly randomized 1:1 to either IVUS guidance or…
- Trial name
- ULTIMATE (NCT02215915)
- Testing
- Angiography, IVUS, DES implantation
- Where
- China
- Volunteers
- 1,448 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
Coronary Artery Disease, Coronary Artery Stenosis Stent
Deep Learning CAD Screening on Chest CT
Coronary artery disease (CAD) is one of the leading causes of death worldwide. Many people have early atherosclerosis without symptoms, and some may develop significant coronary stenosis before any warning signs appear.
- Trial name
- CAD-AI (NCT07181512)
- Testing
- Deep Learning Analysis of Non-contrast Chest CT
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Yifan Guo
Coronary Artery Disease
Safety and Effectiveness of the Coronary Momo Stent
This study evaluates the safety and effectiveness of the Momo Cobalt Chromium stent system for the treatment of single de novo lesions in a native coronary artery.
- Trial name
- NCT01535625
- Testing
- Momo stent
- Where
- 6 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- be Medical
Coronary Artery Disease
Drug-coated Balloon Treatment
Evaluation of the efficacy and clinical outcomes of drug-eluting balloon therapy in ticyaici coronary artery disease.
- Trial name
- DCB-ONE TR (NCT07794839)
- Testing
- drug coated balloon, drug eluting stent
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Coronary Artery Disease, Ischemic Heart Disease
Yonsei OCT (Optical Coherence Tomography) Registry for Evaluation of Efficacy and Safety of Coronary Stenting
Optical coherence tomography (OCT) has been recently studied for evaluation of coronary stenting. Because of high resolutions, several reports have shown that OCT is appropriate for evaluating neointimal tissue after coronary…
- Trial name
- NCT02099162
- Testing
- coronary stents
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Yonsei University
Coronary Artery Disease
A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.
The main objective of this study is to assess the safety and effectiveness of the Cypher™ sirolimus-eluting stent in reducing angiographic in-lesion late loss in patients with an in-stent restenotic native coronary artery lesion.
- Trial name
- TROPICAL (NCT00232856)
- Testing
- drug-eluting stent
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 162 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)
An open-label, prospective, single-arm study is designed to evaluate safety, clinical and technical efficacy of the CorPath 200 System in delivery and manipulation of the coronary guide wires and balloon/stent systems for use in…
- Trial name
- NCT01076036
- Testing
- CorPath 200
- Where
- Colombia
- Volunteers
- 8 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Coronary Artery Disease
JACTAX LD Drug Eluting Stent Trial
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
- Trial name
- NCT00754975
- Testing
- JACTAX LD DES, TAXUS™ Libertè™ DES
- Where
- 5 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
BiOSS LIM C vs 2nd Generation DES in Non-LM Bifurcations
Coronary bifurcations are encountered in about 15 - 20% of percutaneous coronary interventions (PCI). They are considered technically challenging and associated with worse clinical outcomes than non-bifurcation lesions.
- Trial name
- POLBOS 3 (NCT03548272)
- Testing
- Percutaneous Coronary Intervention with stent implantation
- Where
- Poland
- Volunteers
- 518 people
- Sponsor
- Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland
Coronary Artery Disease, Atherosclerosis
Drug-eluting Balloon in Acute Myocardial Infarction
The investigators hypothesize that patients with Acute ST Elevation Myocardial Infarction may benefit from primary angioplasty with use of a drug eluting balloon/bare metal stent combination without impairing the process of…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Thrombosis, Acute Myocardial Infarction
- Trial name
- DEB-AMI (NCT00856765)
- Testing
- Drug eluting balloon, Bare metal stent, Drug eluting stent
- Where
- 2 sites in Italy, Netherlands
- Volunteers
- 150 people
- Sponsor
- UMC Utrecht
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Atherosclerosis, Coronary Artery Disease
The OMEGA Clinical Trial
The purpose of this study is to evaluate the safety and effectiveness of the OMEGA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion.
- Trial name
- NCT01419171
- Testing
- OMEGA™ Monorail Coronary Stent System
- Where
- 37 sites in United States, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting SeQuent Please S stent system (DEBlue) in the treatment of stenoses in native coronary arteries with nominal stent diameters between ≥ 2.5 mm and…
- Trial name
- PEPCADIII (NCT00473772)
- Testing
- DEBlue stent vs. Cypher stent
- Where
- 16 sites in Belgium, Czechia and 6 more
- Volunteers
- 643 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Disease
COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)
This First In Man study is a prospective, multicentre, single blind, randomized, controlled clinical trial of the CINATRA™ ISA 247 Coated Coronary Stent System as compared to the CINATRA™ Coronary Stent System.
- Trial name
- CONFIRM 1 (NCT00689767)
- Testing
- CINATRA™ Coronary Stent System, CINATRA™ ISA 247 Coated Coronary Stent System
- Where
- 7 sites in Belgium
- Volunteers
- 103 people
- Sponsor
- Atrium Medical Corporation